Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
Top Cited Papers
Open Access
- 1 November 2003
- journal article
- other
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (11) , 1088-1093
- https://doi.org/10.1136/ard.62.11.1088
Abstract
Objective: To determine the prevalence of systemic sclerosis associated pulmonary arterial hypertension (SScPAH), evaluate outcome, and identify predictors of mortality in a large patient cohort. Methods: A prospective four year follow up study of 794 patients (722 from our own unit and 72 referrals). All patients screened for PAH using a combination of echocardiography, lung function testing, and clinical assessment. Patients with suspected raised pulmonary artery systolic pressures of >35 mm Hg, carbon monoxide transfer factor (Tlco) 20% over a one year period with no pulmonary fibrosis, and patients with SSc with breathlessness with no pulmonary fibrosis found were investigated with right heart catheterisation. All patients with SScPAH were treated in accordance with current best practice. Results: The prevalence of PAH was 12% (89/722) by right heart catheter. The survival was 81%, 63%, and 56% at 1, 2, and 3 years from the diagnosis (in 89 patients from our own cohort and 59/72 referrals). Haemodynamic indices of right ventricular failure—raised mRAP (hazard ratio 21), raised mPAP (hazard ratio 20), and low CI (hazard ratio 11) predicted an adverse outcome There was no significant difference in survival between patients with SScPAH with (n=40) and without (n=108) pulmonary fibrosis (p=0.3). Conclusions: The prevalence of SScPAH in this cohort was similar to that of other catheter based studies and lower than that of previous echo based studies. The 148 patients with SScPAH actively treated had comparable outcomes to those of the cohorts with primary pulmonary hypertension. A high mRAP was the strongest haemodynamic predictor of mortality. To improve prognosis, future treatments need to be implemented at an earlier disease stage to prevent right ventricular decompensation.Keywords
This publication has 28 references indexed in Scilit:
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary HypertensionCirculation, 1997
- Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary HypertensionCirculation, 1996
- Survival in primary pulmonary hypertension. Validation of a prognostic equation.Circulation, 1994
- Pulmonary Arterial Hypertension Responsive to Immunosuppressive Therapy in Systemic Lupus ErythematosusLupus, 1993
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes.Japanese Circulation Journal, 1992
- Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue diseaseThe American Journal of Cardiology, 1991
- Pulmonary hypertension in the crest syndrome variant of systemic sclerosisArthritis & Rheumatism, 1986